CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
BP reduction with the sodium glucose co-transporter 2 inhibitor (SGLT-2i) empagliflozin (EMPA) in type 2 diabetes (T2D) is similar in treatment naïve as in those on one or ≥2 antihypertensive agents – further insights from a dedicated 24h…
DOI 10.1055/s-0035-1549550
Bibliografische Angaben
Nachweis in CareLit
Autor:innenG Mancia, CP Cannon, I Tikkanen, C Zeller, L Ley, T Hach, HJ Woerle, UC Broedl, OE Johansen
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Objective: EMPA is a new glucose-lowering agent of the SGLT2i class, which reduces body weight and also lowers BP. We assessed the EMPA-related BP lowering effect under background antihypertensive treatment. Methods: This was a 12-week study involving 823 T2D patients (mean ± SD age 60.2 ± 9.0 years, HbA1c 7.9 ± 0.7%, office systolic (S)/diastolic (D) BP 142.1 ± 12.3/83.9 ± 7.0 mmHg, in the full analysis set). EMPA…
Zitieren
Zitierempfehlung
G Mancia, CP Cannon, I Tikkanen, C Zeller, L Ley, T Hach, HJ Woerle, UC Broedl, OE Johansen (2015) BP reduction with the sodium glucose co-transporter 2 inhibitor (SGLT-2i) empagliflozin (EMPA) in type 2 diabetes (T2D) is similar in treatment naïve as in those on one or ≥2 antihypertensive agents – further insights from a dedicated 24h ABPM study. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549550
Mit CareLit weiterarbeiten